PMID- 23124710
OWN - NLM
STAT- MEDLINE
DCOM- 20131021
LR  - 20180816
IS  - 1099-1077 (Electronic)
IS  - 0885-6222 (Linking)
VI  - 28
IP  - 1
DP  - 2013 Jan
TI  - Single ketamine infusion in bipolar depression resistant to antidepressants: are 
      neurotrophins involved?
PG  - 87-90
LID - 10.1002/hup.2271 [doi]
AB  - OBJECTIVES: We investigated serum brain-derived neurotrophin factor (BDNF), nerve 
      growth factor (NGF), neurotrophin-3 (NTF3), neurotrophin-4 (NTF4) and the 
      glial-derived neurotrophic factor (GDNF), in relation to ketamine efficacy, in 
      bipolar depressed patients resistant to treatment with antidepressants. METHODS: 
      Twenty-five patients (4 male, 21 female), aged 27-67 years, with bipolar 
      depression, receiving mood-stabilizing medications, were studied. Antidepressants 
      were discontinued for at least 7 days before single intravenous ketamine infusion 
      (0.5 mg/kg body weight). Response to ketamine was defined as >/= 50% reduction on 
      17-item Hamilton Depression Rating Scale (HDRS) after 1 week, and remission as 
      HDRS score </= 7. Serum BDNF, NGF, NTF3, NTF4 and GDNF levels were estimated by 
      enzyme-linked immunosorbent assay. RESULTS: There were 13 ketamine responders and 
      12 non-responders. The remission was obtained in eight and 12 patients after 
      seven and 14 days, respectively. At baseline, there were no differences between 
      responders and non-responders in any of the neurotrophins. Serum BDNF was 
      significantly reduced after 7 days in non-responders. Serum NGF, NT3, NT4 and 
      GDNF did not significantly change. CONCLUSIONS: The results confirm an 
      antidepressant effect of ketamine infusion as an add-on to mood-stabilizing drugs 
      in bipolar depression resistant to antidepressant treatment. They may also 
      suggest a possible involvement of BDNF in this effect.
CI  - Copyright (c) 2012 John Wiley & Sons, Ltd.
FAU - Rybakowski, Janusz K
AU  - Rybakowski JK
AD  - Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, 
      Poland. rybakows@wlkp.top.pl
FAU - Permoda-Osip, Agnieszka
AU  - Permoda-Osip A
FAU - Skibinska, Maria
AU  - Skibinska M
FAU - Adamski, Rafal
AU  - Adamski R
FAU - Bartkowska-Sniatkowska, Alicja
AU  - Bartkowska-Sniatkowska A
LA  - eng
PT  - Journal Article
DEP - 20121105
PL  - England
TA  - Hum Psychopharmacol
JT  - Human psychopharmacology
JID - 8702539
RN  - 0 (Antidepressive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Nerve Growth Factors)
RN  - 690G0D6V8H (Ketamine)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents/*administration & dosage
MH  - Biomarkers/blood
MH  - Bipolar Disorder/*drug therapy/*metabolism/psychology
MH  - Brain-Derived Neurotrophic Factor/blood/*physiology
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Ketamine/*administration & dosage/pharmacology
MH  - Male
MH  - Middle Aged
MH  - Nerve Growth Factors/*physiology
MH  - Treatment Outcome
EDAT- 2012/11/06 06:00
MHDA- 2013/10/22 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/06/01 00:00 [received]
PHST- 2012/09/27 00:00 [accepted]
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2013/10/22 06:00 [medline]
AID - 10.1002/hup.2271 [doi]
PST - ppublish
SO  - Hum Psychopharmacol. 2013 Jan;28(1):87-90. doi: 10.1002/hup.2271. Epub 2012 Nov 
      5.